TMCnet News
TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007REGULATED INFORMATION Transparency notifications Leuven (Belgium) - January 16, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") announced today that it received transparency notifications pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions. Summary of the notifications It concerns the following two notifications:
1. Content of the notification by Bank of America Corporation Date of the notification: January 11, 2018. Reason of the notification: acquisition of voting securities or voting rights/acquisition of financial instruments that are treated as voting securities. Person subject to the notification requirement: Bank of America Corporation (with address at Wilmington, D.E., USA), who is a parent undertaking/controlling person. Date on which the threshold was crossed: January 5, 2018.
Denominator: 274,287,190. Details of the notification: following the acquisition of voting securities or voting rights and the acquisition of financial instruments that are treated as voting securities, the number of voting rights was as follows:
and the number of equivalent financial instruments was as follows:
Total: 13,424,331 voting rights and 1,068,270 voting rights that may be acquired if the instrument is exercised (5.28% of the total number of voting rights). Chain of controlled undertakings through which the holdings are effectively held: Merrill Lynch International, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Bank of America, National Association are controlled by Bank of America Corporation. Bank of America Corporation is not a controlled entity. *** 2. Content of the notification by Sand Grove Capital Management LLP Date of the notification: January 12, 2018. Reason of the notification: acquisition of voting securities or voting rights. Person subject to the notification requirement: Sand Grove Capital Management LLP (with address at 4th floor, 35 Dover Street, London W1S 4NQ, UK), a person that notifies alone. Date on which the threshold was crossed: January 8, 2018. Threshold that was crossed: 5%. Denominator: 274,287,190. Details of the notification: following the acquisition of voting securities or voting rights, the number of voting rights was as follows:
Chain of controlled undertakings through which the holding is effectively held: Sand Grove Capital Management LLP is not a controlled entity. Additional information: Sand Grove Capital Management LLP acts as investment manager for the Sand Grove Opportunities Master Fund Ltd and the Sand Grove Tactical Fund LP. Sand Grove Capital Management LLP can exercise voting rights at its discretion without any instruction from its clients. This press release and the above-mentioned transparency notifications can be consulted on our website:
For more information: TiGenix About TiGenix TiGenix NV (Euronext Brussels and NASDAQ: TIG) is an advanced biopharmaceutical company developing novel therapies for serious medical conditions by exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells. TiGenix lead product, Cx601, has successfully completed a European Phase III clinical trial for the treatment of complex perianal fistulas - a severe, debilitating complication of Crohn's disease. Cx601 received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) and a global Phase III trial intended to support a future U.S. Biologic License Application (BLA) started in 2017. TiGenix has entered into a licensing agreement with Takeda, a global pharmaceutical company active in gastroenterology, under which Takeda acquired the exclusive right to develop and commercialize Cx601 for complex perianal fistulas outside the U.S. TiGenix' second adipose-derived product, Cx611, is undergoing a Phase I/II trial in severe sepsis - a major cause of mortality in the developed world. TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain) and Cambridge, MA (USA). For more information, please visit http://www.tigenix.com. |